(R)-methoxy-succinic acid | 3966-55-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-methoxy-succinic acid
• 英文别名: (R)-Methoxy-bernsteinsaeure；rechtsdrehende Methoxy-bernsteinsaeure；Methylaether-d-aepfelsaeure；(R)-methoxy-succinic acid；D(+)-Methoxybernsteinsaeure；(2R)-2-methoxybutanedioic acid
• CAS: 3966-55-0
• 化学式: C₅H₈O₅
• 分子量: 148.116
• InChiKey: GTWJUDXIBMRDNK-GSVOUGTGSA-N

物化性质

• 沸点：
  277.7±25.0 °C(Predicted)
• 密度：
  1.383±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-methoxy-succinic acid 在 乙酰氯 作用下， 反应 48.0h， 以87.6%的产率得到(R)-3-methoxy-dihydro-furan-2,5-dione
  参考文献：
  名称：

  [EN] PYRIDAZINONES AS GPR119 AGONISTS
  [FR] PYRIDAZINONES UTILISÉS COMME AGONISTES DU RÉCEPTEUR GPR-119

  摘要：

  公开号：

  WO2011138427A3
• 作为产物：
  描述：

  2-甲氧基丁二酸 在 番木鳖碱 作用下， 生成 (R)-methoxy-succinic acid
  参考文献：
  名称：

  Purdie; Bolam, Journal of the Chemical Society, 1895, vol. 67, p. 949,951

  摘要：

  DOI：

文献信息

• Evolution of a Strategy for the Total Synthesis of (+)‐Cornexistin
  作者：Raphael E. Wildermuth、Christian Steinborn、David M. Barber、Kim S. Mühlfenzl、Mario Kendlbacher、Peter Mayer、Klaus Wurst、Thomas Magauer

  DOI：10.1002/chem.202101849

  日期：2021.8.19

  an early stage with installation of the maleic anhydride as late as possible. The successful approach featured an intermolecular NHK coupling to install the Z-alkene, a syn-Evans-aldol reaction to forge the stereocenters along the eastern periphery, an intramolecular allylic alkylation to close the nine-membered carbocycle, and a challenging stepwise hydrolysis of a β-keto nitrile to furnish the maleic

  本文详细介绍了(+)-cornexistin的首次全合成的进展。最初的努力是将反应性马来酸酐部分掩蔽为 3,4-取代呋喃，并在分子内 Conia-ene 或 Nozaki-Hiyama-Kishi (NHK) 反应中形成九元碳环。这些策略的产量较低，并受到Z-烯烃的后期安装以及东部外围立构中心的危害。这些问题通过采用手性池策略得到解决，该策略涉及在早期阶段构建 C2、C3 和 C8 处的关键立体中心，并尽可能晚地安装马来酸酐。该成功的方法包括通过分子间NHK偶联来安装Z-烯烃，通过顺式-埃文斯-羟醛反应来沿着东部外围形成立体中心，通过分子内烯丙基烷基化来闭合九元碳环，以及具有挑战性的逐步水解β-酮腈以提供马来酸酐。
• Glucagon antagonists/inverse agonists
  申请人：——

  公开号：US20040024045A1

  公开（公告）日：2004-02-05

  A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

  一种新型化合物，能够拮抗胰高血糖素在胰高血糖素受体上的作用。由于这些化合物能够拮抗胰高血糖素受体的作用，因此它们可能适用于治疗和/或预防任何需要拮抗胰高血糖素作用有益的疾病和疾病，例如高血糖症，1型糖尿病，2型糖尿病，脂质代谢紊乱，如血脂异常和肥胖症。
• Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
  申请人：Grauert Matthias

  公开号：US08772323B2

  公开（公告）日：2014-07-08

  The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的吡啶并咪唑酮衍生物，其中A、G和R1基团如申请中所定义，其互变异构体、立体异构体、混合物和盐具有有价值的药理特性，特别是与GPR119受体结合并调节其活性。
• PYRIDAZINONES AS GPR119 AGONISTS
  申请人：Grauert Matthias

  公开号：US20130172323A1

  公开（公告）日：2013-07-04

  The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R 1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的吡啶并咪唑酮衍生物，其中A、G和R1基团如本申请中所定义，其互变异构体、立体异构体、其混合物和其盐，具有有价值的药理特性，特别是能够结合GPR119受体并调节其活性。
• Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide Receptor
  作者：János T. Kodra、Anker Steen Jørgensen、Birgitte Andersen、Carsten Behrens、Christian Lehn Brand、Inger Thøger Christensen、Mette Guldbrandt、Claus Bekker Jeppesen、Lotte B. Knudsen、Peter Madsen、Erica Nishimura、Christian Sams、Ulla G. Sidelmann、Raymon A. Pedersen、Francis C. Lynn、Jesper Lau

  DOI：10.1021/jm7015599

  日期：2008.9.11

  Optimization of a new series of small molecule human glucagon receptor (hGluR) antagonists is described. In the process of optimizing glucagon receptor antagonists, we counter-screened against the closeli related human gastric inhibitory polypeptide receptor (hGIPR), and through structure activity analysis, we obtained compounds with low nanomolar affinities toward the hGluR, which were selective against the hGIPR and the human glucagon-like peptide-1 receptor (hGLP-1R). In the best cases, we obtained a >50 fold selectivity for the hGluR over the hGIPR and a > 1000 fold selectivity over the hGLP-1R. A potent and selective glucagon receptor antagonist was demonstrated to inhibit glucagon-induced glycogenolysis in primary rat hepatocytes as well as to lower glucagon-induced hyperolycemia in Sprague-Dawley rats. Furthermore. the compound was shown to lower blood glucose in the ob/ob mouse after oral dosing.